全文获取类型
收费全文 | 2956篇 |
免费 | 171篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 75篇 |
妇产科学 | 76篇 |
基础医学 | 534篇 |
口腔科学 | 110篇 |
临床医学 | 238篇 |
内科学 | 584篇 |
皮肤病学 | 33篇 |
神经病学 | 296篇 |
特种医学 | 116篇 |
外科学 | 238篇 |
综合类 | 19篇 |
预防医学 | 268篇 |
眼科学 | 34篇 |
药学 | 242篇 |
中国医学 | 24篇 |
肿瘤学 | 254篇 |
出版年
2023年 | 36篇 |
2022年 | 100篇 |
2021年 | 140篇 |
2020年 | 90篇 |
2019年 | 89篇 |
2018年 | 100篇 |
2017年 | 88篇 |
2016年 | 101篇 |
2015年 | 82篇 |
2014年 | 139篇 |
2013年 | 163篇 |
2012年 | 267篇 |
2011年 | 263篇 |
2010年 | 135篇 |
2009年 | 138篇 |
2008年 | 192篇 |
2007年 | 199篇 |
2006年 | 175篇 |
2005年 | 147篇 |
2004年 | 94篇 |
2003年 | 125篇 |
2002年 | 101篇 |
2001年 | 16篇 |
2000年 | 8篇 |
1999年 | 16篇 |
1998年 | 12篇 |
1997年 | 11篇 |
1995年 | 13篇 |
1994年 | 6篇 |
1993年 | 10篇 |
1992年 | 7篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1987年 | 2篇 |
1986年 | 9篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1980年 | 3篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 7篇 |
1973年 | 4篇 |
1972年 | 5篇 |
1970年 | 3篇 |
1967年 | 3篇 |
排序方式: 共有3154条查询结果,搜索用时 15 毫秒
1.
Estrogenic microenvironment generated by organochlorine residues in adipose mammary tissue modulates biomarker expression in ERα-positive breast carcinomas
下载免费PDF全文
![点击此处可从《Breast cancer research : BCR》网站下载免费的PDF全文](/ch/ext_images/free.gif)
2.
3.
Milena Soares Santos Guilherme de Sousa Ribeiro Tainara Queiroz Oliveira Renan Cardoso Nery Santos Edilane Gouveia Kátia Salgado Daniele Takahashi Cleuber Fontes Leila Carvalho Campos Mitermayer Galvão Reis Albert Icksang Ko Joice Neves Reis 《International journal of infectious diseases》2009,13(4):456-461
4.
5.
Milena G. J. Jahoda Helen Brandenburg Titia Cohen-Overbeek Frans J. Los Eva S. Sachs Juriy W. Wladimiroff 《American journal of medical genetics. Part A》1993,46(5):483-485
Data from 4,300 consecutive cases following prenatal diagnosis by transcervical (TC) CVS (n = (1,570) and transabdominal (TA) CVS (n = 2,370) were evaluated. In the follow-up study only infants examined by a physician were included. Gestational age varied between 8.5 and 11.6 weeks (mean 10.3 weeks) for TC-CVS and between 9.3 and 20 weeks (mean 12.3 weeks) for TA-CVS 98% of TC-CVS was performed at 9–10 weeks, 80.7% of TA-CVS procedures were carried out at 12–15 weeks. Selective termination took place in 97 cases of TC-CVS (6.1%) and in 72 cases of TA-CVS (2.6%). Another 8 Women had a termination for psychosocial reasons, resulting in 4,123 (1,469 TC, 2,645 TA) continuing pregnancies. The overall fetal loss rare <28 weeks was 5.4% (n = 80) for TC-CVS and 2.6% (n = 70) for TA-CVS. The overall incidence of congenital abnormalities after birth was 0.9%. Two terminal transversal limb defects were detected in the TC-CVS group (0.14%) against one (0.04%) in the TA-CVS group. © 1993 Wiley-Liss, Inc. 相似文献
6.
Christopher L. Hansen Richard A. Goldstein Olakunle O. Akinboboye Daniel S. Berman Elias H. Botvinick Keith B. Churchwell C. David Cooke James R. Corbett S. James Cullom Seth T. Dahlberg Regina S. Druz Edward P. Ficaro James R. Galt Ravi K. Garg Guido Germano Gary V. Heller Milena J. Henzlova Mark C. Hyun Lynne L. Johnson April Mann Benjamin D. McCallister Robert A. Quaife Terrence D. Ruddy Senthil N. Sundaram Raymond Taillefer R. Parker Ward John J. Mahmarian 《Journal of nuclear cardiology》2007,14(6):e39-e60
7.
8.
Vasculogenic mimicry has no prognostic significance in pT3 and pT4 cutaneous melanoma 总被引:4,自引:0,他引:4
Massi D Franchi A Paglierani M Ketabchi S Borgognoni L Reali UM Santucci M 《Human pathology》2004,35(4):496-502
The concept of vasculogenic mimicry has been introduced to define periodic acid-Schiff (PAS)-positive channels and loops lined by tumor cells, instead of endothelium, able to contribute to microcirculation in uveal melanomas. Previous studies have shown that the PAS-positive patterns are associated with a poor prognosis in uveal melanoma. The aim of the current study was to investigate whether vasculogenic mimicry has a prognostic impact in pT3 and pT4 cutaneous melanoma. Fifteen patients with pT3 and pT4 cutaneous melanoma who did not experience progression after 10 years of follow-up and 30 matched controls who underwent progression were selected. Tumor sections were stained with PAS reaction, omitting the nuclear counterstaining. For immunohistochemistry, sections were stained with CD31, CD105 (endoglin), and laminin. Differences in the distribution of the PAS-positive patterns and a series of clinicopathological variables were evaluated by the Pearson chi(2) and Mann-Whitney U tests. We observed PAS-positive linear sheets, arcs, elliptical loops, and networks encircling roundish to oval aggregates of melanoma cells. The overall distribution of the PAS-positive patterns did not match with the blood microvessels' architecture as detected by immunohistochemical analysis. No statistically significant differences in the distribution of PAS-positive patterns were found between cases and controls. The presence of a parallel pattern correlated significantly with thickness (P = 0.04), whereas an inverse correlation was found with vessel area (P = 0.05). In conclusion, our results suggest that there is a mismatch between vasculogenic mimicry and tumor angiogenesis and do not support any prognostic role of vasculogenic mimicry in thick cutaneous melanoma. 相似文献
9.
Maria Rosaria Raspollini Gianni Amunni Alessandro Villanucci Francesca Castiglione Duccio Rossi Degl'Innocenti Gianna Baroni Milena Paglierani Gian Luigi Taddei 《Applied immunohistochemistry & molecular morphology》2006,14(2):181-186
The bcl-2 protein is a membrane protein involved in prolonging cell survival by inhibiting apoptosis. The HER-2 oncogene, which is located on chromosome 17 and encodes for a tyrosine-kinase growth factor receptor, is amplified and HER-2/neu is overexpressed in 25% to 30% of breast carcinomas. The authors analyzed the bcl-2 expression and the bcl-2 gene and HER-2/neu overexpression and amplification in FIGO stage IIIC, serous, G3, ovarian carcinomas obtained from living patients who had no evident disease 5 years after primary treatment compared with ovarian carcinomas obtained from patients, matched for stage, grade of differentiation, and treatment, who had died of progression of disease no later than 2 years after primary treatment. bcl-2 overexpression was statistically correlated with progression of disease during first-line chemotherapy (P=0.021). The HER-2/neu status was found not to correlate with progression of disease during first-line chemotherapy. Both bcl-2 and HER-2/neu expression were not statistically associated with the clinical outcome of ovarian cancer patients. Gene amplification of the HER-2/neu chromosome 17 was found in all the HER-2/neu, 3+ score, positive-staining ovarian carcinomas. None of the analyzed samples revealed a translocation t(14;18)(q32;q21) in the bcl-2 gene. The knowledge of additional prognostic or even predictive factors, such as bcl-2 expression, in patients with advanced ovarian carcinoma before the primary chemotherapeutic treatment may help in the management of patients who require a more tailored treatment. In addition, the gene amplification of the HER-2/neu suggests that HER-2 is a potential target for treatment in ovarian cancer. 相似文献
10.
Apoptotic defects and impaired clearance of cellular debris are considered key events in the development of autoimmunity,
as they can contribute to autoantigen overload, and may initiate an autoimmune response. The pentraxins are a group of highly
conserved proteins including the short pentraxins, C-reactive protein (CRP) and serum amyloid-P (SAP), and the long pentraxin-3
(PTX3), which are all involved in innate immunity and in acute-phase responses. Mannan-binding lectin (MBL) is an activator
of the complement system, and Apolipoprotein A-1 (Apo A-1) is pivotal in the cholesterol homeostasis and has anti-inflammatory
properties. In addition to their role in innate immunity and inflammation, each of these five proteins participates in the
removal of damaged and apoptotic cells. In this review, we discuss the clinical significance of different levels of these
proteins, their role in the induction or protection from autoimmunity, and the presence of specific autoantibodies against
them in the different autoimmune diseases. 相似文献